Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes
Authors
Yang, Jennie H MWard-Hartstonge, Kirsten A
Perry, Daniel J
Blanchfield, J Lori
Posgai, Amanda L
Wiedeman, Alice E
Diggins, Kirsten
Rahman, Adeeb
Tree, Timothy I M
Brusko, Todd M
Levings, Megan K
James, Eddie A
Kent, Sally C
Speake, Cate
Homann, Dirk
Long, S Alice
Document Type
Journal ArticlePublication Date
2022-01-28
Metadata
Show full item recordAbstract
Cytometric immunophenotyping is a powerful tool to discover and implement T-cell biomarkers of type 1 diabetes (T1D) progression and response to clinical therapy. Although many discovery-based T-cell biomarkers have been described, to date, no such markers have been widely adopted in standard practice. The heterogeneous nature of T1D and lack of standardized assays and experimental design across studies is a major barrier to the broader adoption of T-cell immunophenotyping assays. There is an unmet need to harmonize the design of immunophenotyping assays, including those that measure antigen-agnostic cell populations, such that data collected from different clinical trial sites and T1D cohorts are comparable, yet account for cohort-specific features and different drug mechanisms of action. In these Guidelines, we aim to provide expert advice on how to unify aspects of study design and practice. We provide recommendations for defining cohorts, method implementation, as well as tools for data analysis and reporting by highlighting and building on selected successes. Harmonization of cytometry-based T-cell assays will allow researchers to better integrate findings across trials, ultimately enabling the identification and validation of biomarkers of disease progression and treatment response in T1D.Source
Yang JHM, Ward-Hartstonge KA, Perry DJ, Blanchfield JL, Posgai AL, Wiedeman AE, Diggins K, Rahman A, Tree TIM, Brusko TM, Levings MK, James EA, Kent SC, Speake C, Homann D, Long SA; Immunology of Diabetes Society T-Cell Cytometry Group. Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes. Eur J Immunol. 2022 Mar;52(3):372-388. doi: 10.1002/eji.202049067. Epub 2022 Jan 28. PMID: 35025103; PMCID: PMC9006584.DOI
10.1002/eji.202049067Permanent Link to this Item
http://hdl.handle.net/20.500.14038/52065PubMed ID
35025103Rights
© 2022 Wiley-VCH GmbH.ae974a485f413a2113503eed53cd6c53
10.1002/eji.202049067